Bendamustine plus Rituximab versus R-miniCHOP: which is better for unfit patients with diffuse larger B-cell lymphoma?

Click to increase image sizeClick to decrease image size

Authors’ contributions

YHD and LLZ conceived and designed the study. DDZ collected and analyzed the data, wrote the manuscript, LLZ revised the manuscript. All authors read and approved the final manuscript.

Data availability statement

The clinical data supporting the conclusions of this manuscript will be made available by the authors.

Disclosure statement

No potential conflict of interest was reported by the authors.

Ethics committee approval

This study was approved by the Ethics and Scientific Committee of Hubei University of Medicine (XYY2021002) and was performed according to the Good Clinical Practice Guidelines and the Helsinki Declaration. Informed consent was obtained from all subjects involved in the study.

Additional information

Funding

This study was supported by grant from the National Natural Science Foundation of China (No. 81672940), and Innovative Research Program of Xiangyang No.1 People’s Hospital (Grants number: XYY2021Q02).